Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Commonly prescribed antidepressants may be associated with protection against severe COVID-19. The mechanism of their action in this context, however, remains unknown. Here, I investigated the effect of an antidepressant drug fluvoxamine on membrane trafficking of the SARS-CoV-2 spike protein and its cell host receptor ACE2 in HEK293T cells. A sub-therapeutic concentration (80 nM) of fluvoxamine rapidly upregulated fluid-phase endocytosis, resulting in enhanced accumulation of the spike-ACE2 complex in enlarged early endosomes. Diversion of endosomal trafficking provides a simple cell biological mechanism consistent with the protective effect of antidepressants against COVID-19, highlighting their therapeutic and prophylactic potential.
Article activity feed
-
-
SciScore for 10.1101/2021.06.15.448391: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Recombinant SARS-CoV-2 spike protein and the anti-spike mouse polyclonal antibody were kindly provided by Dr. Paul F. anti-spikesuggested: NoneThe following rabbit antibodies were used: anti-EEA1, anti-ACE2 (GeneTex), anti-EEA1suggested: (GeneTex Cat# GTX50769, RRID:AB_11163294)The following antibody dilutions (v/v) were used: 1/1000 (anti-spike), 1/1000 (anti-6xHis), 1/500 (anti-ACE2), 1/400 (anti-EEA1), 1/400 (anti-LAMP1). anti-LAMP1suggested: NoneFor spike protein uptake measurements, … SciScore for 10.1101/2021.06.15.448391: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Recombinant SARS-CoV-2 spike protein and the anti-spike mouse polyclonal antibody were kindly provided by Dr. Paul F. anti-spikesuggested: NoneThe following rabbit antibodies were used: anti-EEA1, anti-ACE2 (GeneTex), anti-EEA1suggested: (GeneTex Cat# GTX50769, RRID:AB_11163294)The following antibody dilutions (v/v) were used: 1/1000 (anti-spike), 1/1000 (anti-6xHis), 1/500 (anti-ACE2), 1/400 (anti-EEA1), 1/400 (anti-LAMP1). anti-LAMP1suggested: NoneFor spike protein uptake measurements, cells were fixed, immunostained with the anti-6xHis antibody for 30 min to label the surface pool, permeabilized, immunostained with an anti-spike antibody for 30 min to label the total spike pool. anti-6xHissuggested: NoneFollowing fixation and permeabilization, coverslips were labelled with the anti-ACE2 antibody to visualise the total pool of ACE2. anti-ACE2suggested: NoneFinally, coverslips were incubated with the anti-rabbit-Alexa Fluor 488 and anti-mouse Alexa Fluor 594 secondary antibodies for 30 min. anti-rabbit-Alexasuggested: Noneanti-mousesuggested: NoneExperimental Models: Cell Lines Sentences Resources Cell culture and uptake assays: HEK293T cells were cultured in DMEM supplemented with 10% bovine serum. HEK293Tsuggested: NoneSoftware and Algorithms Sentences Resources Quantification of the images was carried out in ImageJ. ImageJsuggested: (ImageJ, RRID:SCR_003070)Statistical analysis was carried out using the Prism 6.0c software package (GraphPad Software). Prismsuggested: (PRISM, RRID:SCR_005375)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-